355Fluorouracil and high-dose leucovorin with radiotherapy as adjuvant therapy for rectal cancer

Abstract

The purpose of this phase I1 study was to evaluate the efficacy and toxicity of fluorouracil and high-dose leucovorin (S-FU/LV) with pelvic irradiation as adjuvant therapy for patients with macroscopical resected rectal or recto-sigmoid cancer. Following surgery for stages 11-111 primary (52) or recurrent rectal cancer (4), 56 patients received 8 cycles of S-FU/LV and pelvic irradiation. 5-FU doses were 200 mgr/m2 for cycles 2-3 and 300 mgr/m2 for cycles 1 and 4-8. LV doses remained fixed at 200 mgr/m2. Pelvic radiation was started in the third week, between the first and second cycle. The total dose was 50.4 Gy. No severe complications had been recorded. The incidence of grade 3 diarrhea was 19%. Three patients presented leukopenia grade 3 (5%)). In 44 patients (78%) the planned treatment could be administered. The median follow-up was 40 months (range 22-66). Seven patients had a local relapse (13%) and 6 developed distant metastasis ( 10%)). The 3-year disease-free survival was 72%) and the overall survival was 76%. These preliminary results show that combined post-operative S-FU/LV and pelvic radiotherapy are well tolerated and present a reasonable local control and survival rates. This adjuvant treatment should be evaluated in randomized trials.